Marker Therapeutics Advances in Clinical Trials and Finances

Marker Therapeutics (MRKR) has released an update.

Marker Therapeutics is making strides in its clinical and financial fronts with significant progress in its Phase 1 APOLLO study for lymphoma and a financial boost from two NIH grants. As they gear up to release preliminary data, the company remains focused on advancing its T cell-based therapies for challenging cancers.

For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.